指南与共识其他结缔组织病

2017年美国风湿病学会糖皮质激素诱导性骨质疏松症预防和治疗指南

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
指南 / 共识 · Arthritis Rheumatol · 2017-06-06

该指南针对长期(≥3个月)接受糖皮质激素治疗的成人患者,系统评价了预防和治疗糖皮质激素诱导性骨质疏松症(GIOP)的证据,采用GRADE方法评级证据质量并通过专家组共识形成推荐。大多数推荐为条件性推荐,包括低骨折风险者仅用钙和维生素D,中高骨折风险者加用口服双膦酸盐等抗骨质疏松药物,并针对特殊人群提出推荐。

要点

  • 低骨折风险成人仅推荐钙和维生素D治疗。
  • 中高骨折风险成人推荐钙和维生素D加口服双膦酸盐(首选)或其他抗骨质疏松药物。
  • 口服双膦酸盐不适用者应继续钙和维生素D并换用其他抗骨折药物。

核心结论

  • 该指南为长期糖皮质激素治疗患者GIOP的预防和治疗提供了方向性推荐,强调医患共同决策。
  • 大多数推荐为条件性推荐,因证据有限,获益与风险的平衡不确定。

研究设计与样本

  • 通过系统评价综合GIOP预防和治疗措施的获益与危害证据,采用GRADE方法评级证据质量,并经专家组共识确定最终推荐及强度。

主要发现

  • 低骨折风险成人仅用钙和维生素D治疗。
  • 中高骨折风险成人使用钙和维生素D加一种额外抗骨质疏松药物(口服双膦酸盐首选)。
  • 口服双膦酸盐不适用者继续钙和维生素D并换用其他抗骨折药物。
  • 完成计划口服双膦酸盐疗程但仍继续糖皮质激素治疗者,继续口服双膦酸盐或换用其他抗骨折药物。
  • 对儿童、器官移植者、育龄女性及接受极高剂量糖皮质激素者等特殊人群也提出了推荐。

关键数值与推荐

  • 长期糖皮质激素治疗定义为≥3个月。
  • 低骨折风险成人:仅钙和维生素D。
  • 中高骨折风险成人:钙和维生素D加口服双膦酸盐(首选)或其他抗骨质疏松药物。
  • 口服双膦酸盐不适用:继续钙和维生素D,换用其他抗骨折药物。
  • 完成计划口服双膦酸盐疗程但继续糖皮质激素:继续口服双膦酸盐或换用其他抗骨折药物。

临床怎么用

  • 对开始或继续长期糖皮质激素治疗的患者进行初始评估和再评估。
  • 根据骨折风险分层选择预防和治疗方案,低风险者仅用钙和维生素D,中高风险者加用抗骨质疏松药物。
  • 考虑患者价值观、偏好和合并症,进行医患共同决策。
  • 不应用这些推荐限制或拒绝患者获得治疗。

局限性

  • 证据有限,大多数推荐为条件性推荐,获益与危害的平衡不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). METHODS: We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group consensus process to determine the final recommendations and grade their strength. The guideline addresses initial assessment and reassessment in patients beginning or continuing long-term (≥3 months) glucocorticoid (GC) treatment, as well as the relative benefits and harms of lifestyle modification and of calcium, vitamin D, bisphosphonate, raloxifene, teriparatide, and denosumab treatment in the general adult population receiving long-term GC treatment, as well as in special populations of long-term GC users. RESULTS: Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendations in this guideline are conditional (uncertain balance between benefits and harms). Recommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D but switching from an oral bisphosphonate to another antifracture medication in adults in whom oral bisphosphonate treatment is not appropriate, and continuing oral bisphosphonate treatment or switching to another antifracture medication in adults who complete a planned oral bisphosphonate regimen but continue to receive GC treatment. Recommendations for special populations, including children, people with organ transplants, women of childbearing potential, and people receiving very high-dose GC treatment, are also made. CONCLUSION: This guideline provides direction for clinicians and patients making treatment decisions. Clinicians and patients should use a shared decision-making process that accounts for patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017. PMID: 28585373. doi:10.1002/art.40137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。